about
Laboratory testing for platelet antibodiesLow-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.A novel method for simultaneous analysis of specific platelet antibodies: SASPA.Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes.Immunologic and structural analysis of eight novel domain-deletion beta3 integrin peptides designed for detection of HPA-1 antibodies.Modification of solid phase red cell adherence assay for the detection of platelet antibodies in patients with thrombocytopenia.Detection of human platelet antigen-1a alloantibodies in cases of fetomaternal alloimmune thrombocytopenia using recombinant β3 integrin fragments coupled to fluorescently labeled beads.Current problems and future directions of transfusion-induced alloimmunization: summary of an NHLBI working group.Mass-scale high-throughput multiplex polymerase chain reaction for human platelet antigen single-nucleotide polymorphisms screening of apheresis platelet donors.Identification of platelet refractoriness in oncohematologic patients.Reactions Induced by Platelet Transfusions.Human platelet antigen allele frequencies and new mutations on platelet glycoprotein genes in the Chinese Han population.Genotyping of HPA-1 to -7 and -15 in the Thai population using multiplex PCR.Prevalence of the HPA-18w to -21w alleles in the Chinese Han population.A V740L mutation in glycoprotein IIb defines a novel epitope (War) associated with fetomaternal alloimmune thrombocytopenia.Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome.Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.Cross-match-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets.Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions.Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigensAntibodies against human platelet alloantigens and human leucocyte antigen class 1 in Saudi Arabian multiparous women and multi-transfused patients.The haematology of indigenous Australians.Clinical relevance of the HLA system in blood transfusion.Placental immunology and maternal alloimmune responses.Platelet and granulocyte alloimmunisation in multitransfused Tunisian patients.Prevalence of risk factors for platelet transfusion refractoriness in multitransfused hemato-oncological patients at tertiary care center in North India.Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products.Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products.Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.Human platelet antigen genotyping of platelet donors in southern Brazil.Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
P2860
Q27006810-15C9C136-6970-4F89-9D79-7F853D55D9A0Q30539028-37179858-0BD9-4ACC-8EB6-25914CD0472DQ33363850-E17A7089-9599-48CA-B877-B635EAA24B05Q33365275-61B8F901-4FA5-45F3-846E-C4C07F95C25CQ33377595-213F3C4A-7379-423F-9C59-7D62CB4522D5Q33380740-8E8B6A39-CD3B-440F-90B8-B8016C15CE7FQ33393340-94AD2ABC-D760-4906-B473-71A0E1245949Q33393730-EB61CDC8-4C76-4CD0-99DA-31A84B9F8A29Q33394444-37C4DE3E-D35A-4690-A140-FFE0CFFC72F9Q33394648-4587EDDD-7D0B-4A82-8356-6AF172041B3DQ33395008-E7A1242C-08E5-4444-A0FC-F9E2ED4F57B2Q33395703-AE4A9647-0E76-4621-A4CB-8232A9A60606Q33400637-83E8064E-70D4-454D-B0DE-7E187FF35ACCQ33402678-58739921-7BA3-4E9A-9EFD-F8AD9454B65BQ33405220-E73E180B-EEEC-4FE6-AEE1-7BA451FFF7B2Q33407420-C369A872-FB44-4552-AFCB-5154690A3947Q33411662-DFB3E9F9-2A53-4956-B6CF-3FC2744F6D6AQ33412070-12291709-22F5-48AB-B200-6C6C2D2561B3Q33432719-3190F532-B161-41F0-BFC3-6EE4EBFC6A49Q34824419-D9483919-164B-4A0D-A7DF-999F7C39A014Q35681149-9A4B105F-EEE0-4B55-811C-577386D6FAAFQ36069469-C274C383-8CB0-496C-8F10-5E7922E2C809Q37871065-9713E2E3-648E-40F7-8E04-CAE881A262B6Q37925148-3E16BDF8-FFCC-4469-A495-EA3895352E29Q39469941-902A6570-AAAB-4495-808B-0A0D40FB661CQ40167716-39F15C93-8374-442C-996F-7C58D39F5CDDQ45136674-9A907311-43B7-4575-BC5D-AB74C4812F50Q47965299-AA087F1E-7801-4A61-80FF-72BBEA437AEFQ48128391-69B1CCCA-3EC3-4D1F-B30B-42B5C682AF8EQ48154312-A3FA298D-9A94-4AD5-8753-805BB26DCC4FQ50458242-569C887C-47AA-4E49-9841-EEA986DA9C8E
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Platelet alloantibodies in transfused patients.
@ast
Platelet alloantibodies in transfused patients.
@en
Platelet alloantibodies in transfused patients.
@nl
type
label
Platelet alloantibodies in transfused patients.
@ast
Platelet alloantibodies in transfused patients.
@en
Platelet alloantibodies in transfused patients.
@nl
prefLabel
Platelet alloantibodies in transfused patients.
@ast
Platelet alloantibodies in transfused patients.
@en
Platelet alloantibodies in transfused patients.
@nl
P2093
P2860
P1433
P1476
Platelet alloantibodies in transfused patients.
@en
P2093
P2860
P304
P356
10.1046/J.1537-2995.2001.41060766.X
P577
2001-06-01T00:00:00Z